Literature DB >> 33879110

Extra-abdominal desmoid tumor fibromatosis: a multicenter EMSOS study.

Pierluigi Cuomo1,2, Guido Scoccianti3, Alberto Schiavo3, Valentina Tortolini4, Catrin Wigley5, Francesco Muratori3, Davide Matera3, Mariia Kukushkina6, Philipp Theodor Funovics7, Marie-Theres Lingitz7, Reinhard Windhager7, Sander Dijkstra8, Jorrit Jasper8, Daniel A Müller9, Dominik Kaiser9, Tamás Perlaky10, Andreas Leithner11, Maria Anna Smolle11, Domenico Andrea Campanacci3.   

Abstract

BACKGROUND: Extra-abdominal desmoid tumor fibromatosis (DTF) is a rare, locally aggressive soft tissue tumour. The best treatment modality for this patient cohort is still object of debate. QUESTIONS/
PURPOSE: This paper aimed to (1) to compare the outcomes of DTF after different treatment modalities, (2) to assess prognostic factors for recurrence following surgical excision, and (3) to assess prognostic factors for progression during observation.
METHODS: This was a retrospective multicenter study under the patronage of the European Musculoskeletal Oncology Society (EMSOS). All seven centres involved were tertiary referral centres for soft tissue tumours. Baseline demographic data was collected for all patients as well as data on the diagnosis, tumour characteristics, clinical features, treatment modalities and whether they had any predisposing factors for DTF.
RESULTS: Three hundred eighty-eight patients (240 female, 140 male) with a mean age of 37.6 (±18.8 SD, range: 3-85) were included in the study. Two hundred fifty-seven patients (66%) underwent surgical excision of ADF, 70 patients (18%) were observed without therapy, the residual patients had different conservative treatments. There were no significant differences in terms of tumour recurrence or progression between the different treatment groups. After surgical excision, younger age, recurrent disease and larger tumour size were risk factors for recurrence, while tumours around the shoulder girdle and painful lesions were at risk of progression in the observational group.
CONCLUSION: Local recurrence rate after surgery was similar to progression rates under observation. Hence, observation in DTF seems to be justified, considering surgery in case of dimensional progression in 2 consecutive controls (3 and 6 months) and in painful lesions, with particular attention to lesions around the shoulder girdle.

Entities:  

Year:  2021        PMID: 33879110     DOI: 10.1186/s12885-021-08189-6

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  19 in total

1.  Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy.

Authors:  M T Ballo; G K Zagars; A Pollack; P W Pisters; R A Pollack
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

2.  Extremity and trunk desmoid tumors: a multifactorial analysis of outcome.

Authors:  N B Merchant; J J Lewis; J M Woodruff; D H Leung; M F Brennan
Journal:  Cancer       Date:  1999-11-15       Impact factor: 6.860

Review 3.  Extra-abdominal desmoid fibromatosis: A review of management, current guidance and unanswered questions.

Authors:  N Eastley; T McCulloch; C Esler; I Hennig; J Fairbairn; A Gronchi; R Ashford
Journal:  Eur J Surg Oncol       Date:  2016-02-19       Impact factor: 4.424

4.  Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution.

Authors:  A Gronchi; P G Casali; L Mariani; S Lo Vullo; M Colecchia; L Lozza; R Bertulli; M Fiore; P Olmi; M Santinami; J Rosai
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

5.  Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group.

Authors:  A Gronchi; C Colombo; C Le Péchoux; A P Dei Tos; A Le Cesne; A Marrari; N Penel; G Grignani; J Y Blay; P G Casali; E Stoeckle; F Gherlinzoni; P Meeus; C Mussi; F Gouin; F Duffaud; M Fiore; S Bonvalot
Journal:  Ann Oncol       Date:  2013-12-09       Impact factor: 32.976

Review 6.  Abdominal desmoid tumors.

Authors:  George H Sakorafas; Christos Nissotakis; George Peros
Journal:  Surg Oncol       Date:  2007-08-24       Impact factor: 3.279

7.  The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population.

Authors:  J J Reitamo; P Häyry; E Nykyri; E Saxén
Journal:  Am J Clin Pathol       Date:  1982-06       Impact factor: 2.493

8.  Treatment of aggressive fibromatosis: a retrospective study of 72 patients followed for 1-27 years.

Authors:  Annemette Sørensen; Johnny Keller; Ole S Nielsen; Olaf M Jensen
Journal:  Acta Orthop Scand       Date:  2002-04

Review 9.  Margins in extra-abdominal desmoid tumors: a comparative analysis.

Authors:  Andreas Leithner; Markus Gapp; Katharina Leithner; Roman Radl; Peter Krippl; Alfred Beham; Reinhard Windhager
Journal:  J Surg Oncol       Date:  2004-06-01       Impact factor: 3.454

10.  A desmoid tumor-staging system separates patients with intra-abdominal, familial adenomatous polyposis-associated desmoid disease by behavior and prognosis.

Authors:  James Church; Craig Lynch; Paul Neary; Lisa LaGuardia; Elodie Elayi
Journal:  Dis Colon Rectum       Date:  2008-03-06       Impact factor: 4.585

View more
  3 in total

Review 1.  Evolving strategies for management of desmoid tumor.

Authors:  Richard F Riedel; Mark Agulnik
Journal:  Cancer       Date:  2022-06-07       Impact factor: 6.921

2.  Extra-Abdominal Desmoid-Type Fibromatosis Mimicking Myxofibrosarcoma.

Authors:  Ye Rin Kim; Yu Sung Yoon; Hyerim Park
Journal:  J Belg Soc Radiol       Date:  2022-09-21       Impact factor: 1.912

3.  Cryotherapy in extra-abdominal desmoid tumors: A systematic review and meta-analysis.

Authors:  Bimal Mayur Kumar Vora; Peter L Munk; Nagavalli Somasundaram; Hugue A Ouellette; Paul I Mallinson; Adnan Sheikh; Hanis Abdul Kadir; Tien Jin Tan; Yet Yen Yan
Journal:  PLoS One       Date:  2021-12-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.